A test-negative, case-control study assessing effectiveness against symptomatic SARS-CoV-2 infection during Delta-dominant and Omicron-dominant periods in Japan
Latest Information Update: 09 Aug 2022
At a glance
- Drugs Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms FASCINATE
Most Recent Events
- 09 Aug 2022 New trial record
- 03 Aug 2022 Results published in the Clinical Infectious Diseases